{"url_path":"/sec/ird/8-k/2026-06-16/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-16","source_url":"https://www.sec.gov/Archives/edgar/data/1228627/0001140361-26-025363-index.html","accession_number":"0001140361-26-025363","cik":"0001228627","ticker":"IRD","issuer_name":"Opus Genetics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1228627/0001140361-26-025363-index.html","primary_entity_key":"0001228627","primary_entity_name":"Opus Genetics, Inc."},"word_count":188,"has_tables":true,"body_markdown":"Item 7.01\n\nRegulation FD Disclosure.\n\n \n\nAs previously announced, management of Opus Genetics, Inc., a Delaware corporation (the “Company”), delivered a corporate presentation at its Virtual R&D Science Forum held on June 16, 2026. A webcast of the presentation is accessible through the investor relations section of\nthe Company’s website. The presentation is attached hereto as Exhibit 99.1 and incorporated herein by reference. The Company has also made the presentation available to investors on the “Events” section of the Company’s website at\nhttps://ir.opusgtx.com.\n\n \n\nThe information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of\nSection 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any\nfiling made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing. The Company undertakes no obligation to\nupdate, supplement, or amend the materials attached hereto as Exhibit 99.1."}